Quick Answer
Aprea Therapeutics, Inc. reported Operating Income Loss of -$13.23 million for the year ending 2025.
- Aprea Therapeutics, Inc. showed an increase of +7.6% in Operating Income Loss from 2024 to 2025.
- This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Aprea Therapeutics, Inc.'s Operating Income Loss has grown by 64.7%.
- Historical annual values: Fiscal year 2025: -$13.23 million | Fiscal year 2024: -$14.32 million | Fiscal year 2023: -$15.47 million | Fiscal year 2022: -$113.39 million | Fiscal year 2021: -$37.45 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: